

Statement on discontinuation of the study

Sponsor: University College London

EudraCT no: 2009-013638-26

Title of Trial: MESO-02: A phase I/II study of first line vorinostat with pemetrexed-cisplatin, in patients with malignant pleural mesothelioma

Investigational Medicinal Products: Vorinostat, Pemetrexed and Cisplatin

Trial Sites: N/A

Publications: N/A

Statement on discontinuation of the study: Trial abandoned during set-up by the sponsor (University College London) due to withdrawal of industry support. No sites activated and no patients entered the study, therefore no data/results are available.